Clinical Trial

GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-IM-1）

Study acronym: BTC-IM-1
Recruiting
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and immune microenvironment changes in treatment-naïve advanced biliary tract cancer (BTC) patients receiving first-line standard therapy with gemcitabine/cisplatin (GemCis) combined with PD-1/PD-L1 inhibitors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-16.
Status change: Not Yet Recruiting → Recruiting 2025-05-22
Trial Details
NCT Number NCT06988592
Lead Sponsor Fudan University
Conditions Advanced Biliary Tract Cancer
Enrollment 100 participants
Start Date 2025-05-23
Primary Completion 2027-05-18 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-29